BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 18027227)

  • 1. Strategies for including patients recruited during interim analysis of clinical trials.
    Faldum A; Hommel G
    J Biopharm Stat; 2007; 17(6):1211-25. PubMed ID: 18027227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adaptive group sequential test for clinical trials with changing patient population.
    Feng H; Shao J; Chow SC
    J Biopharm Stat; 2007; 17(6):1227-38. PubMed ID: 18027228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of adaptive sample size adjustment with respect to stopping criteria and time of interim analysis.
    Jahn-Eimermacher A; Hommel G
    Stat Med; 2007 Mar; 26(7):1450-61. PubMed ID: 16900553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of adaptive allocation rules for group-sequential binary response clinical trials.
    Morgan CC; Stephen Coad D
    Stat Med; 2007 Apr; 26(9):1937-54. PubMed ID: 16981177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accounting for interim safety monitoring of an adverse event upon termination of a clinical trial.
    Dallas MJ
    J Biopharm Stat; 2008; 18(4):631-8; discussion 439-45. PubMed ID: 18607795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increasing the sample size when the unblinded interim result is promising.
    Chen YH; DeMets DL; Lan KK
    Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Group sequential t-test for clinical trials with small sample sizes across stages.
    Shao J; Feng H
    Contemp Clin Trials; 2007 Sep; 28(5):563-71. PubMed ID: 17434814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing the sample size at interim for a two-sample experiment without Type I error inflation.
    Dunnigan K; King DW
    Pharm Stat; 2010; 9(4):280-7. PubMed ID: 19764040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation in flexible two stage designs.
    Brannath W; König F; Bauer P
    Stat Med; 2006 Oct; 25(19):3366-81. PubMed ID: 16220489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Issues in designing flexible trials.
    Posch M; Bauer P; Brannath W
    Stat Med; 2003 Mar; 22(6):953-69. PubMed ID: 12627412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sample size re-estimation in group-sequential response-adaptive clinical trials.
    Morgan CC
    Stat Med; 2003 Dec; 22(24):3843-57. PubMed ID: 14673942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stopping boundaries adjusted for sample size reestimation and negative stop.
    Shun Z
    J Biopharm Stat; 2002 Nov; 12(4):485-502. PubMed ID: 12477071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flexible two-stage design with sample size reassessment for survival trials.
    Desseaux K; Porcher R
    Stat Med; 2007 Nov; 26(27):5002-13. PubMed ID: 17577242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials.
    Hung HM; Wang SJ; O'Neill R
    J Biopharm Stat; 2007; 17(6):1201-10. PubMed ID: 18027226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Data-driven analysis strategies for proportion studies in adaptive group sequential test designs.
    Wassmer G
    J Biopharm Stat; 2003 Nov; 13(4):585-603. PubMed ID: 14584710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive statistical analysis following sample size modification based on interim review of effect size.
    Hung HM; Cui L; Wang SJ; Lawrence J
    J Biopharm Stat; 2005; 15(4):693-706. PubMed ID: 16022173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal designs for estimating the interesting part of a dose-effect curve.
    Miller F; Guilbaud O; Dette H
    J Biopharm Stat; 2007; 17(6):1097-115. PubMed ID: 18027219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-designing trial combined with classical group sequential monitoring.
    Yin G; Shen Y
    J Biopharm Stat; 2005; 15(4):667-75. PubMed ID: 16022171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stopping clinical trials early for benefit: impact on estimation.
    Freidlin B; Korn EL
    Clin Trials; 2009 Apr; 6(2):119-25. PubMed ID: 19342463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.